NCT00083915View on ClinicalTrials.gov

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

PHASE3CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

Cisplatin

20mg/m2 continuous infusion days -3 and -2.

DRUG

Cyclophosphamide

800 mg/m2 continuous infusion days -3 and -2.

DRUG

Adriamycin

20mg/m2 continuous infusion -3 and -2.

DRUG

Etoposide

80mg/m2 continuous infusion -3 and -2.

DRUG

Melphalan

200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.

DRUG

Thalidomide

200mg PO Continuing to Day +5, then hold until platelets \>50 thousand (K).

DRUG

Dexamethasone

40 mg po days 1 - 4 (4 days)

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/MIRT, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00083915 - DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | Biotech Hunter | Biotech Hunter